Atea Pharmaceuticals (AVIR) Income towards Parent Company (2019 - 2026)

Atea Pharmaceuticals' Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$45.4 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 32.59% year-over-year to -$45.4 million in Q1 2026; TTM through Mar 2026 was -$169.5 million, a 21.53% decrease from a year earlier, with the FY2025 full-year figure at -$158.3 million, up 5.96% from the prior year.
• Income towards Parent Company declined to -$45.4 million in Q1 2026 per AVIR's latest filing, from -$44.9 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$8.1 million in Q3 2022 and bottomed at -$63.2 million in Q1 2024.
• The 5-year median for Income towards Parent Company is -$35.5 million (2023), against an average of -$36.7 million.
• Biggest YoY gain for Income towards Parent Company was 71.39% in 2022; the steepest drop was 2136.06% in 2022.
• Year by year, Income towards Parent Company stood at -$34.4 million in 2022, then retreated by 13.75% to -$39.2 million in 2023, then advanced by 14.35% to -$33.5 million in 2024, then plunged by 33.76% to -$44.9 million in 2025, then decreased by 1.28% to -$45.4 million in 2026.
• Per Business Quant, the three latest AVIR Income towards Parent Company figures stand at -$45.4 million (Q1 2026), -$44.9 million (Q4 2025), and -$42.0 million (Q3 2025).